Retinol-binding protein 4 and plasminogen activator inhibitor-1 as potential prognostic biomarkers of non-allergic asthma caused by obesity in adolescents

• JoséJ. Leija-Martínez ^[1] ; Karla L. Patricio-Román ^[2] ; Blanca E. Del-Río-Navarro ^[1] ; Salvador Villalpando-Carrión ^[4] ; Juan Antonio Reyes-Garay ^[2] ; Juan Manuel Vélez Reséndiz ^[3] ; Rodrigo Romero-Nava ^[2] ; Fausto Sanchéz-Muñoz ^[1] ; Santiago Villafaña ^[3] ; Onofre Muñoz-Hernández ^[1] ; Enrique Hong ^[5] ; Maria Esther Ocharan Hernández ^[3] ; Fengyang Huang ^[1]
  1. [1] Universidad Nacional Autónoma de México

     Universidad Nacional Autónoma de México

     México

     
  2. [2] Hospital Infantil de México Federico Gómez

     Hospital Infantil de México Federico Gómez

     México

     
  3. [3] Instituto Politécnico Nacional

     Instituto Politécnico Nacional

     México

     
  4. [4] Hospital Infantil de México Federico Gómez, Department of Gastroenterology and Nutrition, Mexico City, Mexico.
  5. [5] Department of Pharmacobiology, Centro de Investigacion de Estudio Avanzados del Instituto Politecnico Nacional, Mexico City, Mexico.

  Mostrar afiliaciones +
• Localización: Allergologia et immunopathologia: International journal for clinical and investigate allergology and clinical immunology, ISSN-e 1578-1267, ISSN 0301-0546, Vol. 49, Nº. 3, 2021, págs. 21-29
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Background: Non-allergic asthma caused by obesity is a complication of the low-grade chronic inflammation inherent in obesity. Consequently, the serum concentrations of adipokines such as retinol-binding protein 4 (RBP4) and plasminogen activator inhibitor-1 (PAI-1) increase. No gold standard molecule for the prediction of non-allergic asthma among obese patients has been identified.

    Objective: To evaluate RBP4 and PAI-1 as prognostic biomarkers of non-allergic asthma caused by obesity.

    Methods: A cross-sectional study between four groups of adolescents: (1) healthy (n = 35), (2) allergic asthma without obesity (n = 28), (3) obesity without asthma (n = 33), and (4) non-allergic asthma with obesity (n = 18).

    Results: RBP4 was higher in the non-allergic asthma with obesity group than in the obesity without asthma group (39.2 ng/mL [95% confidence interval (CI): 23.8–76.0] vs. 23.5 ng/mL [95% CI: 3.2–33.5], p < 0.01), and PAI-1 was higher in the non-allergic asthma with obesity group than in the obesity without asthma group (21.9 ng/mL [95% CI: 15.7–26.5] vs. 15.9 ng/mL [95% CI: 9.4–18.2], p < 0.05). Receiver operating characteristic (ROC) curve analysis demonstrated that the serum RBP4 cut-off value was >42.78 ng/mL, with an area under the ROC curve (AUC) of 0.741 (95% CI: 0.599–0.853, p = 0.001), considered acceptable. The PAI-1 cut-off value was >12.0 ng/mL, with an AUC of 0.699 (95% CI: 0.554–0.819, p = 0.008), considered fair.

    Conclusions: RBP4 may be useful to predict non-allergic asthma among obese adolescents in clinical practice.